Return to Vaccination News Home Page  __»   Right-click to "open in new window"

Subscribe to the Vaccination NewsLetter

View past & current Scandals (columns by Sandy Mintz)

Search This Site using keywords

http://www.sciencedirect.com/science?_ob=ArticleURL&_aset=W-WA-A-A-VW-MsSAYWW-UUA-AUCZUBEWYY-AUCVDWVDD-VW-U&_rdoc=4&_fmt=summary&_udi=B6TCN-45BCRDW-2&_coverDate=05%2F15%2F2002&_cdi=5175&_orig=search&_st=13&_sort=d&view=c&_acct=C000000593&_version=1&_urlVersion=0&_userid=127913&md5=4ec491a0c48105d6b24b66d27c7ccbfd

Go to ScienceDirect® Home Skip Main Navigation Links
 Register or Login:   Password:     Athens Login 
HomeBrowse JournalsBrowse Abstract DatabasesBrowse Reference WorksMy AlertsMy Profile Help (Opens new window)
1 of 1 Result ListNo Previous DocumentNo Next Document

Toxicology
Volume 174, Issue 1 , 15 May 2002, Pages 37-43


  This Document
  Abstract
  Full Text + Links
  PDF (100 K)
 
  Actions
  E-mail Article
 


doi:10.1016/S0300-483X(02)00055-0    How to cite or link using doi (opens new window) Cite or link using doi  
Copyright © 2002 Published by Elsevier Science Ireland Ltd. All rights reserved.

 

Non-clinical vaccine safety assessment

 

François VerdierCorresponding Author Contact Information, E-mail The Corresponding Author

Aventis Pasteur, Campus Merieux, 1541 Avenue Marcel Mérieux, 69280 Marcy L'Etoile, France

Available online 12 March 2002.


 

Abstract

As vaccines are undoubtedly classified as pharmaceuticals, they have to be submitted to strict non-clinical safety evaluation. The context of their prophylactic use requires that every effort is made to ensure their safe use. Their safety evaluation is complex as they act through a multistage mechanism in which the vaccine by itself acts as a pro-drug, antibodies and activated lymphocytes being the actual effectors. Therefore, several potential toxicities must be considered: direct toxicity of the test article, toxicity linked to the pharmacodynamic activity of the vaccine, activation of pre-existing disorders, toxicity of contaminants and impurities and other adverse reactions due to interaction between the various components. Guidelines dealing with vaccines include general guidelines applicable to all pharmaceuticals, such as ICH S6, and also more specific documents which allow some flexibility in study design. Among the various studies, if single-dose studies are generally part of the quality control test battery, repeated dose studies are pivotal. The animal model and treatment schedule selection and the parameters investigated are critical for the relevance of this safety assessment. Immunological and safety pharmacology parameters should be adapted to the specific properties of vaccines and added to this type of study. Vaccines intended for pregnant women or women of child-bearing age require embryo-fetal and post-natal studies with an adapted design to obtain appropriate fetal and maternal exposure during gestation with continuation into the post-natal period. Tests exist to detect hypersensitivity or autoimmune reactions, but require further validation. In addition to this tailor-made approach, any adjuvant or active component added to the vaccine formulation necessitate their own assessment using studies routinely performed for new drugs. From this review, vaccine toxicology would appear to be a separate discipline on its own whose predictivity will be increased by new method development.

Author Keywords: Vaccine; Non-clinical safety; Immunotoxicology; Regulatory affairs


 

Corresponding Author Contact Information Tel.: +33-437-37-3181; fax: +33-437-37-9436; email: francois.verdier@aventis.com



 

 
  This Document
  Abstract
  Full Text + Links
  PDF (100 K)
 
  Actions
  E-mail Article
 

Toxicology
Volume 174, Issue 1 , 15 May 2002 , Pages 37-43



 

1 of 1 Result ListNo Previous DocumentNo Next Document
HomeBrowse JournalsBrowse Abstract DatabasesBrowse Reference WorksMy AlertsMy Profile   Help (Opens new window)


 

Send feedback to ScienceDirect
Software and compilation © 2003 ScienceDirect. All rights reserved.
ScienceDirect® is an Elsevier Science B.V. registered trademark.


Your use of this service is governed by Terms and Conditions. Please review our Privacy Policy for details on how we protect information that you supply.

 

Return to Vaccination News Home Page  __»   Right-click to "open in new window"

DISCLAIMER:    All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice.  The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.